Recent Updates
Recently added Catalysts
PODD Negative Sentiment Score: 25/100

PODD Investor Alert: Insulet Corp. Potential Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Company Allegedly Concealed Device Defect: Levi & Korsinsky

Key Takeaway: Insulet Corp. faced a significant stock drop after announcing a voluntary medical device correction for its Omnipod 5 insulin pods, which revealed a design defect causing insulin leakage. This defect has been associated with eighteen serious adverse events, raising concerns about the company's prior knowledge of the issue. Legal investigations are underway regarding potential securities fraud as shareholders seek to address their losses.
Price reaction · baseline $201.49 (2026-04-14 close) · hit after-hours · clean, no other PODD news in the window
day 0 close
+0.5%

Market Sentiment Analysis

CONCERNS & RISKS

  • Insulet Corp. shares dropped approximately 6.9% after the defect disclosure.
  • The defect could lead to serious health issues, including hospitalization.
  • Eighteen serious adverse events were linked to the insulin leakage defect.
  • The company may have concealed the defect prior to the public disclosure.

Full Press Release Details

Insulet Corp. Stock Falls After Voluntary Medical Device Correction Reveals Omnipod 5 Insulin-Leakage Defect Affecting Thousands of Pods
NEW YORK,April 15, 2026/PRNewswire/ -- Insulet Corp. (NASDAQ:PODD) shares dropped approximately 6.9% after the Company filed an 8-K on March 12, 2026, disclosing a voluntary medical device correction covering Omnipod 5 insulin pods due to a design defect that could cause insulin leakage -- a defect linked to eighteen serious adverse events. Shareholders who lost money on their PODD investment are encouraged tosubmit their information here. You may also contact Joseph E. Levi, Esq. via email at[email protected]or by telephone at (212) 363-7500.
The voluntary correction disclosed that the affected pods -- representing roughly 1.5% of annual production -- carried a defect capable of causing insulin leakage leading to hospitalization and diabetic ketoacidosis (DKA). Levi & Korsinsky is investigating whether Insulet and certain executives were aware of the defect prior to the March 12 disclosure, including during the Company's Q4 2025 earnings call on February 18, 2026, where CEO Ashley McEvoy described Omnipod as demonstrating "reliability, consistency and broad appeal" and stated that "real-world outcomes continue to earn prescriber and patient confidence."
The 8-K filing referenced eighteen serious adverse events tied to the defect. The FDA's medical device correction database catalogued the action. No serious adverse events had been referenced in the February 18 prior filing or earnings presentation.
If you purchased Insulet Corp. shares and suffered a loss,click here to discuss your legal rights. You may also contact Joseph E. Levi, Esq. via email at[email protected]or by telephone at (212) 363-7500.
ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.
CONTACT:Levi & Korsinsky, LLPJoseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 27th FloorNew York, NY 10004[email protected]Tel: (212) 363-7500Fax: (212) 363-7171

Frequently Asked Questions

What caused the drop in Insulet Corp. stock?

The stock dropped due to a voluntary medical device correction revealing a defect in Omnipod 5 insulin pods.

What is the defect associated with Omnipod 5?

The defect can cause insulin leakage, which may lead to hospitalization and diabetic ketoacidosis.

How many adverse events are linked to the defect?

Eighteen serious adverse events have been reported in connection with the defect.

Is there an investigation into Insulet Corp.?

Yes, an investigation is underway regarding potential securities fraud related to the defect.

Last updated: Apr 15, 2026